A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy

The aim of evaluating the efficacy and safety of cadonilimab combined with monotherapy chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with negative driver genes who have failed previous immunotherapy is to provide a more effective and safe treatment option for these patients.

Trial Details

NCT ID
NCT06467500
Phase
PHASE2
Sponsor
Xin-Hua Xu
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cadonilimab (AK104)
Locations (sample)
  • Yichang, China|30.71444,111.28472

Key Eligibility Criteria

  • Voluntarily participate in clinical research; Fully understand and be informed of this study and sign the informed consent form;
  • Age ≥ 18 and ≤ 75, male or female;
  • ECOG physical performance score of 0-2;
  • Patients with histologically confirmed squamous or non-squamous advanced non- small cell lung cancer (according to AJCC, 8th edition);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →